Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PMP22 | Q01453 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | KYNU | Q16719 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 5/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 5/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.46 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.46 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4437685 | 1.00 | PMP22 (0.54) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL17613156 | 1.00 | PMP22 (0.54) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL18782794 | 0.82 | PMP22 (0.50) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL18782774 | 0.82 | PMP22 (0.50) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL18782571 | 0.82 | PMP22 (0.50) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL20739371 | 0.81 | PMP22 (0.50) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL8736543 | 0.81 | PMP22 (0.67) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL24485485 | 0.80 | NOS2 (0.39) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL15946195 | 0.80 | NOS2 (0.39) | PMP22NOS2KYNUSLC1A3SLC1A2 | |
| SCHEMBL8778376 | 0.80 | NOS2 (0.39) | PMP22NOS2KYNUSLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140322302-A1 | THERAPEUTIC PEPTIDES | COMBIMAB, INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8748575-B2 | Therapeutic peptides | COMBIMAB, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| US-20140038881-A1 | Therapeutic Peptides | COMBIMAB, INC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-2605786-A2 | THERAPEUTIC PEPTIDES | Combimab, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| WO-2011156453-A2 | THERAPEUTIC PEPTIDES | COMBIMAB, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
| CN-1331674-A | Sulfonamide hydroxamates | HOFFMANN LA ROCHE (CH) | 2002-01-16 | — | — | CN | disclosed |
| US-6329502-B1 | VIRICIDES AGAINST HUMAN IMMUNODEFICIENCY VIRUS; TREATMENT OF AIDS (ACQUIRED IMMUNE DEFICIENCY SYNDROME) | JAPAN ENERGY CORPORATION (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6313094-B1 | COMPOSITION FOR INHIBITING HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | JAPAN ENERGY CORPORATION (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-0490667-B1 | HIV protease inhibitors | JAPAN ENERGY CORP (JP) | 1999-06-09 | — | — | EP | disclosed |
| EP-0490667-A2 | HIV protease inhibitors | JAPAN ENERGY CORPORATION (JP) | 1992-06-17 | — | — | EP | disclosed |
| US-4055653-A | Sulfur containing trialkoxybenzoylamino carboxylic acids | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1977-10-25 | — | — | US | disclosed |
| US-3981910-A | Sulfur containing trialkoxybenzoylamino carboxylic acids | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1976-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140322302-A1 | THERAPEUTIC PEPTIDES | VIP, GMPS, PDE3A | PMP22 1743/4885NOS2 299/4885KYNU 4301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.